TITLE

Translating Efficacy into Effectiveness in Antiretroviral Therapy

AUTHOR(S)
Fletcher, Courtney V.
PUB. DATE
August 2007
SOURCE
Drugs;2007, Vol. 67 Issue 14, p1969
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Durable and sustained suppression of HIV replication can be achieved as demonstrated in several recent clinical trials of antiretroviral (ARV) regimens. However, the efficacy demonstrated in the experimental setting does not always translate to effectiveness in the clinical setting. The frequency and number of medications (conventionally referred to as the pill count) contribute to regimen effectiveness. However, clinicians and HIV-infected patients recognise that there are several other characteristics of an ARV regimen that are equally important contributors to its effectiveness. Potency and durability, the potential for drugdrug interactions, and the occurrence of adverse events also contribute to the effectiveness and complexity of a drug regimen. A comprehensive consideration of factors associated with efficacy will optimise the translation to effectiveness for the individual infected with HIV.
ACCESSION #
27130259

 

Related Articles

  • The Effect of Reducing the Dose of Stavudine on Body Composition, Bone Density, and Markers of Mitochondrial Toxicity in HIV-Infected Subjects: Answers and Questions. Wanke, Christine // Clinical Infectious Diseases;4/15/2008, Vol. 46 Issue 8, p1297 

    The article highlights the study of McComsey on the effects of reducing dose of stavudine on body compositions, bone density and markers of mitochondrial toxity in (Human Immunodeficiency Virus) HIV-infected patients in the U.S. According to the author, the trial has been positive since the dose...

  • Effect of Reducing the Dose of Stavudine on Body Composition, Bone Density, and Markers of Mitochondrial Toxicity in HIV-Infected Subjects: A Randomized, Controlled Study. McComsey, G. A.; Lo Re^III, V.; O'Riordan, M.; Walker, U. A.; Lebrecht, D.; Baron, E.; Mounzer, K.; Frank, I. // Clinical Infectious Diseases;4/15/2008, Vol. 46 Issue 8, p1290 

    Background. Stavudine is widely used in developing countries. Lipoatrophy and mitochondrial toxicity have been linked to stavudine use, but it is unclear whether switching to a lower dose can reduce these toxicities while maintaining human immunodeficiency virus (HIV) suppression. Methods....

  • Healthcare Worker Perceived Barriers to Early Initiation of Antiretroviral and Tuberculosis Therapy among Tanzanian Inpatients. Wajanga, Bahati M. K.; Peck, Robert N.; Kalluvya, Samuel; Fitzgerald, Daniel W.; Smart, Luke R.; Downs, Jennifer A. // PLoS ONE;Feb2014, Vol. 9 Issue 2, p1 

    Setting: Clinical trials have shown that early initiation of antiretroviral therapy in HIV-infected patients with tuberculosis saves lives, but models for implementation of this new strategy have been under-studied in real-world settings. Objective: To identify the barriers and possible...

  • Strategies for Initiating Combination Antiretroviral Therapy. Michael L.#Tapper; Eric S.#Daar; Peter J.#Piliero; Kimberly#Smith; Corklin#Steinhart // AIDS Patient Care & STDs;Apr2005, Vol. 19 Issue 4, p224 

    Numerous potent antiretroviral regimens have proven successful as initial therapy in treat- ment-naïve HIV-infected patients. As the development of new agents makes possible new treatment regimens, providers are faced with increasingly complex questions of when to initiate treatment and which...

  • Early Use of Antiretrovirals May Reduce HIV Transmission. Norman, Kayda // Applied Clinical Trials;Jun2011, Vol. 20 Issue 6, p17 

    The article discusses the findings of a study on a clinical trial known as the HPTN 052 in relation to the early use of oral antiretroviral therapy (ART). It states that the early use of ART may reduce the likelihood that a person with human immunodeficiency virus (HIV) will pass the virus to...

  • Review: Improving Outcomes for Patients with Burkitt Lymphoma and HIV. Blinder, Victoria S.; Chadburn, Amy; Furman, Richard R.; Mathew, Susan; Leonard, John P. // AIDS Patient Care & STDs;Mar2008, Vol. 22 Issue 3, p175 

    Burkitt lymphoma (BL) is a highly aggressive B-cell malignancy that occurs with increased frequency among patients infected with HIV. Until recently, the immunocompromised state of patients with HIV and BL was generally deemed to preclude the use of the intensive chemotherapeutic regimens used...

  • Once-Daily versus Twice-Daily Lopinavir/Ritonavir in Antiretroviral-Naive HIV-Positive Patients: A 48-Week Randomized Clinical Trial. Eron, Joseph J.; Feinberg, Judith; Kessler, Harold A.; Horowitz, Harold W.; Witt, Mallory D.; Carpio, Felix F.; Wheeler, David A.; Ruane, Peter; Mildvan, Donna; Yangco, Bienvenido G.; Bertz, Richard; Bernstein, Barry; King, Martin S.; Sun, Eugene // Journal of Infectious Diseases;1/15/2004, Vol. 189 Issue 2, p265 

    The safety, pharmacokinetics, and antiviral activity of lopinavir, a human immunodeficiency virus (HIV) protease inhibitor, coformulated with ritonavir as a pharmacokinetic enhancer were evaluated in 38 antiretroviral-naive patients randomized 1:1 to receive open-label lopinavir/ritonavir at a...

  • Long-Term Effects of Intermittent IL-2 in HIV Infection: Extended Follow-Up of the INSIGHT STALWART Study. Markowitz, Norman; Lopardo, Gustavo; Wentworth, Deborah; Gey, Daniela; Babiker, Abdel; Fox, Lawrence; Tavel, Jorge // PLoS ONE;Oct2012, Vol. 7 Issue 10, Special section p1 

    Background: The Study of Aldesleukin with and without Antiretroviral Therapy (STALWART) was designed to evaluate whether intermittent IL-2 alone or with peri-cycle ART increased CD4+ cell counts (and so delayed initiation of ART) in HIV infected individuals having ≥300 CD4+ cells/mm³...

  • Development, Validation and Clinical Evaluation of a Low Cost In-House HIV-1 Drug Resistance Genotyping Assay for Indian Patients. Acharya, Arpan; Vaniawala, Salil; Shah, Parth; Misra, Rabindra Nath; Wani, Minal; Mukhopadhyaya, Pratap N. // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Human Immunodeficiency Virus-1 (HIV-1) drug resistance genotyping assay is a part of clinical management of HIV-1 positive individuals under treatment with highly active antiretroviral therapy (HAART). Routine monitoring of drug resistance mutations in resource limited settings like India is not...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics